Paradigm Shifts in Perioperative Management of Colorectal Cancer: Personalization Based on Tumor Biology, Primary Site, and Recurrence Risk, and the Evolving Role of Organ Preservation
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27167261 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Kaoru Yoshikawa und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological Chemotherapy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Neoplasm Recurrence, Local, Precision Medicine, Organ Sparing Treatments. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 188 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Institute Hospital, Japanese Foundation for Cancer Research.
Abstract (Originalsprache)
Perioperative treatment for colorectal cancer (CRC) is undergoing a paradigm shift from uniform cytotoxic regimens toward strategies guided by tumor location, microsatellite instability (MSI)/mismatch repair (MMR) status, and recurrence risk. Four clinically relevant subgroups now shape decision-making: microsatellite stable (MSS)/proficient MMR (pMMR) colon cancer, microsatellite instability-high (MSI-H)/deficient MMR (dMMR) colon cancer, MSS/pMMR rectal cancer, and MSI-H/dMMR rectal cancer. In MSS/pMMR colon cancer, adjuvant therapy is being refined through risk-adapted treatment duration and selective use of neoadjuvant chemotherapy. In MSS/pMMR rectal cancer, total neoadjuvant therapy, selective omission of pelvic radiotherapy, and watch-and-wait strategies are redefining treatment sequencing and organ preservation. In MSI-H/dMMR colon cancer, immune checkpoint inhibitor (ICI) therapy has shown marked activity in both adjuvant and neoadjuvant settings. In MSI-H/dMMR rectal cancer, neoadjuvant ICI therapy is being explored as a non-operative organ preservation strategy. In parallel, circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) assessment is emerging as a tool for postoperative escalation, de-escalation, and surveillance. Across these settings, the maturity of the evidence varies widely, ranging from established phase III standards to guideline-endorsed but still single-arm approaches and investigational strategies that require prospective validation before routine adoption. This review summarizes the current evidence and remaining challenges in biology-, site-, and risk-adapted perioperative management of CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterological Chemotherapy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan.
- Department of Colorectal Surgery, Kanagawa Cancer Center, Yokohama 241-8515, Japan.
- Department of Gastroenterology, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan.
- Department of Gastroenterology, Kanagawa Cancer Center, Yokohama 241-8515, Japan.
ORCID-Profile: Akira Ooki, Eiji Shinozaki, Eiichiro Toyokawa, Manabu Shiozawa, Shin Maeda, Kensei Yamaguchi, Hiroki Osumi
Förderung
- Cancer Institute Hospital, Japanese Foundation for Cancer Research
Zitieren
APA
Yoshikawa, K., Ooki, A., Shinozaki, E., Toyokawa, E., Suzuki, K., Shiozawa, M., Maeda, S., Yamaguchi, K., & Osumi, H. (2026). Paradigm Shifts in Perioperative Management of Colorectal Cancer: Personalization Based on Tumor Biology, Primary Site, and Recurrence Risk, and the Evolving Role of Organ Preservation. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27167261
Vancouver
Yoshikawa K, Ooki A, Shinozaki E, Toyokawa E, Suzuki K, Shiozawa M, et al. Paradigm Shifts in Perioperative Management of Colorectal Cancer: Personalization Based on Tumor Biology, Primary Site, and Recurrence Risk, and the Evolving Role of Organ Preservation. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27167261
BibTeX
@article{Yoshikawa2026,
author = {Yoshikawa, Kaoru and Ooki, Akira and Shinozaki, Eiji and Toyokawa, Eiichiro and Suzuki, Keito and Shiozawa, Manabu and Maeda, Shin and Yamaguchi, Kensei and Osumi, Hiroki},
title = {Paradigm Shifts in Perioperative Management of Colorectal Cancer: Personalization Based on Tumor Biology, Primary Site, and Recurrence Risk, and the Evolving Role of Organ Preservation},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27167261}
}
EUVIMED